Patents by Inventor Lijuan Jiang

Lijuan Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11124438
    Abstract: The present disclosure provides an Alcaligenes faecalis strain capable of degrading ethylene oxide and uses thereof. The deposit number of the strain is CGMCC No. 18435. This strain can be used in pollution treatment, for example, to treat industrial sewage or wastewater containing ethylene oxide, which greatly improves the decontamination ability of ethylene oxide in manufacturing industries. The present disclosure also provides a degradation agent for degrading ethylene oxide and a method for biodegrading ethylene oxide.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 21, 2021
    Assignees: CHIO KANG MEDICAL, INC., QIAOKANG BIOTECH (GUANGDONG) CO., LTD.
    Inventors: Jianlong Xue, Dongxin Hou, Lijuan Jiang, Weiguo Wang, Xuzhong Liao, Yecheng He, Hao Chen, Jiali Lin, Ziping Zhu, Lixiong Feng
  • Patent number: 11085016
    Abstract: The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 10, 2021
    Assignees: CHIO KANG MEDICAL, INC., QIAOKANG BIOTECH (GUANGDONG) CO., LTD.
    Inventors: Jianlong Xue, Dongxin Hou, Xin Yin, Lijuan Jiang, Xuzhong Liao, Guqun Ren, Yecheng He, Ziping Zhu, Jiali Lin, Lixiong Feng
  • Publication number: 20210222117
    Abstract: The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 22, 2021
    Inventors: Jianlong Xue, Dongxin Hou, Xin Yin, Lijuan Jiang, Xuzhong Liao, Guqun Ren, Yecheng He, Ziping Zhu, Jiali Lin, Lixiong Feng
  • Publication number: 20210221718
    Abstract: The present disclosure provides an Alcaligenes faecalis strain capable of degrading ethylene oxide and uses thereof. The deposit number of the strain is CGMCC No. 18435. This strain can be used in pollution treatment, for example, to treat industrial sewage or wastewater containing ethylene oxide, which greatly improves the decontamination ability of ethylene oxide in manufacturing industries. The present disclosure also provides a degradation agent for degrading ethylene oxide and a method for biodegrading ethylene oxide.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 22, 2021
    Inventors: Jianlong Xue, Dongxin Hou, Lijuan Jiang, Weiguo Wang, Xuzhong Liao, Yecheng He, Hao Chen, Jiali Lin, Ziping Zhu, Lixiong Feng
  • Patent number: 9060971
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: June 23, 2015
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang
  • Patent number: 8906853
    Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: December 9, 2014
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, In Jong Kim, Jiang Long, Lijuan Jiang, Sheng Sean Liu, Guoqiang Wang
  • Publication number: 20140154208
    Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Application
    Filed: November 27, 2013
    Publication date: June 5, 2014
    Applicant: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, In Jong Kim, Jiang Long, Lijuan Jiang, Sheng Sean Liu, Guoqiang Wang
  • Publication number: 20110217261
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.
    Type: Application
    Filed: August 5, 2010
    Publication date: September 8, 2011
    Inventors: Yat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang